Spatially graded hydrogels for preclinical testing of glioblastoma anticancer therapeutics

S. Pedron, H. Polishetty, A. M. Pritchard, B. P. Mahadik, Jann N Sarkaria, B. A.C. Harley

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

While preclinical models such as orthotopic tumors generated in mice from patient-derived specimens are widely used to predict sensitivity or therapeutic interventions for cancer, such xenografts can be slow, require extensive infrastructure, and can make in situ assessment difficult. Such concerns are heightened in highly aggressive cancers, such as glioblastoma (GBM), that display genetic diversity and short mean survival. Biomimetic biomaterial technologies offer an approach to create ex vivo models that reflect biophysical features of the tumor microenvironment (TME). We describe a microfluidic templating approach to generate spatially graded hydrogels containing patient-derived GBM cells to explore drug efficacy and resistance mechanisms.

Original languageEnglish (US)
Pages (from-to)442-449
Number of pages8
JournalMRS Communications
Volume7
Issue number3
DOIs
StatePublished - Sep 1 2017

Fingerprint

Hydrogels
Tumors
Biomimetics
Testing
Biocompatible Materials
Microfluidics
Heterografts
Biomaterials
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Materials Science(all)

Cite this

Pedron, S., Polishetty, H., Pritchard, A. M., Mahadik, B. P., Sarkaria, J. N., & Harley, B. A. C. (2017). Spatially graded hydrogels for preclinical testing of glioblastoma anticancer therapeutics. MRS Communications, 7(3), 442-449. https://doi.org/10.1557/mrc.2017.85

Spatially graded hydrogels for preclinical testing of glioblastoma anticancer therapeutics. / Pedron, S.; Polishetty, H.; Pritchard, A. M.; Mahadik, B. P.; Sarkaria, Jann N; Harley, B. A.C.

In: MRS Communications, Vol. 7, No. 3, 01.09.2017, p. 442-449.

Research output: Contribution to journalArticle

Pedron, S, Polishetty, H, Pritchard, AM, Mahadik, BP, Sarkaria, JN & Harley, BAC 2017, 'Spatially graded hydrogels for preclinical testing of glioblastoma anticancer therapeutics', MRS Communications, vol. 7, no. 3, pp. 442-449. https://doi.org/10.1557/mrc.2017.85
Pedron, S. ; Polishetty, H. ; Pritchard, A. M. ; Mahadik, B. P. ; Sarkaria, Jann N ; Harley, B. A.C. / Spatially graded hydrogels for preclinical testing of glioblastoma anticancer therapeutics. In: MRS Communications. 2017 ; Vol. 7, No. 3. pp. 442-449.
@article{0d376a77d01846aba5d28bd0a90ad98f,
title = "Spatially graded hydrogels for preclinical testing of glioblastoma anticancer therapeutics",
abstract = "While preclinical models such as orthotopic tumors generated in mice from patient-derived specimens are widely used to predict sensitivity or therapeutic interventions for cancer, such xenografts can be slow, require extensive infrastructure, and can make in situ assessment difficult. Such concerns are heightened in highly aggressive cancers, such as glioblastoma (GBM), that display genetic diversity and short mean survival. Biomimetic biomaterial technologies offer an approach to create ex vivo models that reflect biophysical features of the tumor microenvironment (TME). We describe a microfluidic templating approach to generate spatially graded hydrogels containing patient-derived GBM cells to explore drug efficacy and resistance mechanisms.",
author = "S. Pedron and H. Polishetty and Pritchard, {A. M.} and Mahadik, {B. P.} and Sarkaria, {Jann N} and Harley, {B. A.C.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1557/mrc.2017.85",
language = "English (US)",
volume = "7",
pages = "442--449",
journal = "MRS Communications",
issn = "2159-6859",
publisher = "Cambridge University Press",
number = "3",

}

TY - JOUR

T1 - Spatially graded hydrogels for preclinical testing of glioblastoma anticancer therapeutics

AU - Pedron, S.

AU - Polishetty, H.

AU - Pritchard, A. M.

AU - Mahadik, B. P.

AU - Sarkaria, Jann N

AU - Harley, B. A.C.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - While preclinical models such as orthotopic tumors generated in mice from patient-derived specimens are widely used to predict sensitivity or therapeutic interventions for cancer, such xenografts can be slow, require extensive infrastructure, and can make in situ assessment difficult. Such concerns are heightened in highly aggressive cancers, such as glioblastoma (GBM), that display genetic diversity and short mean survival. Biomimetic biomaterial technologies offer an approach to create ex vivo models that reflect biophysical features of the tumor microenvironment (TME). We describe a microfluidic templating approach to generate spatially graded hydrogels containing patient-derived GBM cells to explore drug efficacy and resistance mechanisms.

AB - While preclinical models such as orthotopic tumors generated in mice from patient-derived specimens are widely used to predict sensitivity or therapeutic interventions for cancer, such xenografts can be slow, require extensive infrastructure, and can make in situ assessment difficult. Such concerns are heightened in highly aggressive cancers, such as glioblastoma (GBM), that display genetic diversity and short mean survival. Biomimetic biomaterial technologies offer an approach to create ex vivo models that reflect biophysical features of the tumor microenvironment (TME). We describe a microfluidic templating approach to generate spatially graded hydrogels containing patient-derived GBM cells to explore drug efficacy and resistance mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=85032589715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032589715&partnerID=8YFLogxK

U2 - 10.1557/mrc.2017.85

DO - 10.1557/mrc.2017.85

M3 - Article

VL - 7

SP - 442

EP - 449

JO - MRS Communications

JF - MRS Communications

SN - 2159-6859

IS - 3

ER -